SEC filing · 8-K

CNS Pharmaceuticals, Inc.: Executive or director change

CNS Pharmaceuticals announced the voting results from its 2026 annual meeting of stockholders.

Filed October 2, 2026

Neutral news

What happened

Stockholders approved an amendment to the 2020 Equity Plan to increase authorized shares by 650,000 shares.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to CNS Pharmaceuticals, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.